Souhaitez-vous accéder aux communiqués récents ?

HOUSTON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company with the worldwide exclusive license of Multi-Antigen Targeted T cells...

Dublin, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The "Adeno Associated Virus Vector Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...

Dublin, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The "Spine Biologic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's...

Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "Cell Therapy Human Raw Materials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...

Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "Automated and Closed Cell Therapy Processing Systems Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added...

HAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based...

FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study

Dublin, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Cell and Gene Therapy Investment Trends" report has been added to ResearchAndMarkets.com's offering. The market size of...

Dublin, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The "Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing" has been...

NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Juvenile Diabetes Cure Alliance (JDCA), a 501(c)(3) nonprofit solely focused on accelerating a cure for type 1 diabetes, announced the release of the 14th...